Can Gene Therapy Cure Blindness?
Since the approval of the first gene therapy for blindness, there has been a wave…
Since the approval of the first gene therapy for blindness, there has been a wave…
The big US biotech Biogen has agreed to acquire Nightstar Therapeutics for €773M ($877M), including…
UK startup Nightstar Therapeutics has reported good safety and early signs of visual improvements in…
Nightstar Therapeutics will begin the first Phase III trial for a gene therapy targeting choroideremia,…
As the 2017 reports roll in, we're already turning our gaze to 2018. These are…
Nightstar has gone public on the American market with the aim of raising $75M for its…
NightstaRx has raised €39.5M that will go towards three clinical programs testing gene therapies for…
Choroideremia is a rare X-linked recessive retinal disease which eventually leads to blindness. A series…